CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on advancing cell-based therapies using genetically modified natural killer cells to treat cancer. It aims to bridge the gap between basic research and practical applications in the biotech industry, enhancing the effectiveness of these therapies through improved donor-recipient matching and innova…
This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases.
This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products (""ATMPs""), and their use in treatment of cancer refractory to classical therapies.…
MEDIZINISCHE HOCHSCHULE HANNOVER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Norway, Oslo
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Basel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
IRCCS OSPEDALE POLICLINICO SAN MARTINO
Italy, Genova
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
